Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €3.92 EUR
Change Today -0.149 / -3.67%
Volume 0.0
QNMA On Other Exchanges
As of 3:40 PM 04/30/15 All times are local (Market data is delayed by at least 15 minutes).

sequenom inc (QNMA) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/24/15 - €4.27
52 Week Low
05/9/14 - €1.90
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SEQUENOM INC (QNMA)

sequenom inc (QNMA) Related Businessweek News

View More BusinessWeek News

sequenom inc (QNMA) Details

Sequenom, Inc., a life sciences company, develops and commercializes molecular diagnostics testing services for the women's health and oncology markets in the United States and internationally. The company provides molecular based laboratory developed tests (LDTs) comprising MaterniT21 PLUS LDT, a noninvasive prenatal test (NIPT) to detect fetal chromosomal abnormalities; HerediT CF LDT, a carrier screen test to identify individuals with cystic fibrosis or genetic mutations; SensiGene fetal Rhesus D (RhD) LDT, a NIPT to determine the presence or absence of RhD factor by direct detection of the fetal RhD genotype in RhD negative mothers from a maternal blood sample; and VisibiliT LDT, a NIPT to detect fetal chromosomal abnormalities by determining the relative amount of chromosomal material present in circulating cell-free DNA in a maternal blood sample. It also offers a microarray test that uses fetal samples obtained by amniocentesis or chorionic villus sampling under the NextView brand; additional carrier screening tests for Ashkenazi Jewish disorders, spinal muscular atrophy, and fragile X syndrome under the HerediT brand; and RetnaGene age-related macular degeneration (AMD) test to predict the risk of a patient with dry or early stage AMD progressing to wet or advanced choroidal neovascular disease within 2, 5, and 10 years. The company serves physicians and client laboratories. The company was founded in 1994 and is headquartered in San Diego, California.

448 Employees
Last Reported Date: 03/10/15
Founded in 1994

sequenom inc (QNMA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $433.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $343.9K
Chief Scientific & Strategy Officer, Executiv...
Total Annual Compensation: $407.6K
Senior Vice President of Corporate Governance...
Total Annual Compensation: $300.2K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $111.0K
Compensation as of Fiscal Year 2014.

sequenom inc (QNMA) Key Developments

Sequenom Inc. Proposes Amendment to its Restated Certificate of Incorporation

Sequenom Inc. announced that the annual general meeting to be held on June 17, 2015, it has proposed an amendment to the company’s Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 185,000,000 to 275,000,000 shares.

Sequenom Inc. Announces Board Changes

Sequenom Inc. announced that its board of directors elected Kenneth Buechler as chairman of the board, effective April 1, 2015. Dr. Buechler succeeds Harry Hixson, who will retire from the position effective March 31, 2015, after 11 years of service. Incoming chairman, Dr. Buechler, has served on the board of directors since December 2009. Prior to joining Sequenom's board, he served as president and chief scientific officer of Biosite Incorporated.

Sequenom Inc. Announces Board Changes, Effective April 1, 2015

Sequenom Inc. Board of Directors elected Dirk van den Boom, Ph.D., current Executive Vice President, Chief Scientific and Strategy Officer, as a director, effective April 1, 2015. In addition, the Board of Directors appointed Dr. van den Boom to the Science Committee of its Board of Directors, also effective April 1, 2015. Dr. van den Boom will fill the vacancy created by the resignation of Harry F. Hixson, Jr., Ph.D. as a director, which resignation is effective March 31, 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QNMA:GR €3.92 EUR -0.149

QNMA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AtriCure Inc $22.25 USD +0.24
Cerus Corp $4.42 USD -0.02
Luminex Corp $15.84 USD +0.32
Pacific Biosciences of California Inc $5.67 USD +0.51
STAAR Surgical Co $8.73 USD -0.12
View Industry Companies

Industry Analysis


Industry Average

Valuation QNMA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.6x
Price/Book NM Not Meaningful
Price/Cash Flow 535.6x
TEV/Sales 2.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SEQUENOM INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at